Introduction:
Acute lymphoblastic leukemia (ALL) is the most common malignancy among
children. It has a good prognosis after regular treatment. However, the
current treatment of this disease has encountered certain challenges,
one of which is the side effects of chemotherapy drugs associated with
treatment intolerance, including chemotherapy-related pancreatitis.
Asparaginase is significantly associated with pancreatitis, which is
important for the treatment of lymphocytic leukemia and can
significantly improve prognosis. However, the use of asparaginase may be
restricted by the occurrence of drug-induced pancreatitis, which may
result in serious infection, disorder of circulation, pancreatic injury
and multiple organ dysfunction, and may also affect the prognosis of
ALL. [1-3]
Many studies have shown that the incidence of asparaginase-associated
pancreatitis varies from 1.5% to 18%,[4-8] and have explored the
risk factors for pancreatitis in patients receiving chemotherapy, such
as age and the cumulative dosage of asparaginase, etc. But there are
still other drugs associated with pancreatitis and possible risk
factors. Assessment before chemotherapy of the risk of pancreatitis may
be good for preventing pancreatitis from happening, and improving the
prognosis of ALL. This study seeks to develop a tool that can predict
the risk of pancreatitis in children with leukemia treated with the
China Children’s Leukemia Group(CCLG)-ALL regimen, potentially aiding in
early detection and intervention.